Report overview
This report contains market size and forecasts of RNA Interference (RNAi) Drug Delivery in global, including the following market information:
Global RNA Interference (RNAi) Drug Delivery Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global RNA Interference (RNAi) Drug Delivery Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five RNA Interference (RNAi) Drug Delivery companies in 2021 (%)
The global RNA Interference (RNAi) Drug Delivery market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Nanoparticle Drug Delivery Technology Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of RNA Interference (RNAi) Drug Delivery include Metabolic disorders, Alnylam Pharmaceuticals Inc, Merck & Co. Inc, Access Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Calondo Pharmaceuticals Inc, Marina Biotech Inc, RXi Pharmaceuticals Corp and Quark Pharmaceuticals Inc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the RNA Interference (RNAi) Drug Delivery manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global RNA Interference (RNAi) Drug Delivery Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global RNA Interference (RNAi) Drug Delivery Market Segment Percentages, by Type, 2021 (%)
Nanoparticle Drug Delivery Technology
Pulmonary Drug Delivery Technology
Nucleic Acid Drug Delivery Technology
Aptamer Drug Delivery Technology
Global RNA Interference (RNAi) Drug Delivery Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global RNA Interference (RNAi) Drug Delivery Market Segment Percentages, by Application, 2021 (%)
Infectious Diseases
Cardiology
Oncology
Neurology
Ophthalmology
Metabolic Disorders
Global RNA Interference (RNAi) Drug Delivery Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global RNA Interference (RNAi) Drug Delivery Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies RNA Interference (RNAi) Drug Delivery revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies RNA Interference (RNAi) Drug Delivery revenues share in global market, 2021 (%)
Key companies RNA Interference (RNAi) Drug Delivery sales in global market, 2017-2022 (Estimated), (K Units)
Key companies RNA Interference (RNAi) Drug Delivery sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Metabolic disorders
Alnylam Pharmaceuticals Inc
Merck & Co. Inc
Access Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Calondo Pharmaceuticals Inc
Marina Biotech Inc
RXi Pharmaceuticals Corp
Quark Pharmaceuticals Inc
Silence Therapeutics plc
Tacere Therapeutics Inc
PhaseRx Inc
Sirnaomics Inc
Traversa Therapeutics Inc
